GeneDx Holdings (WGS) Cash from Investing Activities (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash from Investing Activities for 7 consecutive years, with -$17.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 83.41% year-over-year to -$17.3 million; the TTM figure through Mar 2026 stood at -$69.4 million (down 71.77% YoY), while the FY2025 annual figure was -$61.5 million, down 104.16% from the prior year.
• Cash from Investing Activities slipped to -$17.3 million in Q1 2026 per WGS's latest filing, from -$11.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $843000.0 in Q1 2024 and bottomed at -$130.3 million in Q2 2022.
• Historically, Cash from Investing Activities has averaged -$17.3 million across 5 years, with a median of -$7.8 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 2807.77% — and 2024, when it jumped 282.47%.
• GeneDx Holdings' Cash from Investing Activities stood at -$2.8 million in 2022, then sank by 71.39% to -$4.9 million in 2023, then soared by 89.33% to -$519000.0 in 2024, then plunged by 2033.33% to -$11.1 million in 2025, then sank by 55.84% to -$17.3 million in 2026.
• Business Quant data shows WGS's Cash from Investing Activities at -$17.3 million in Q1 2026, -$11.1 million in Q4 2025, and -$4.7 million in Q3 2025.